FREELINE Trademark

Trademark Overview

On Monday, November 19, 2018, a trademark application was filed for FREELINE with the United States Patent and Trademark Office. The USPTO has given the FREELINE trademark a serial number of 79252849. The federal status of this trademark filing is REGISTERED as of Tuesday, February 4, 2020. This trademark is owned by Freeline Therapeutics Limited. The FREELINE trademark is filed in the Pharmaceutical Products and Treatment & Processing of Materials Services categories with the following description:

Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others

Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorde...
freeline

General Information

Serial Number79252849
Word MarkFREELINE
Filing DateMonday, November 19, 2018
Status700 - REGISTERED
Status DateTuesday, February 4, 2020
Registration Number5974485
Registration DateTuesday, February 4, 2020
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, November 19, 2019

Trademark Statements

Goods and ServicesPharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others
Description of MarkThe mark consists of the word "FREELINE" in stylised text.
Goods and ServicesPharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases
Pseudo MarkFREE LINE
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 4, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateMonday, March 4, 2019
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameFreeline Therapeutics Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB
Party NameFreeline Therapeutics Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB
Party NameFreeline Therapeutics Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events

Event DateEvent Description
Saturday, February 4, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Saturday, August 6, 2022NEW REPRESENTATIVE AT IB RECEIVED
Friday, June 5, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, May 18, 2020FINAL DISPOSITION NOTICE SENT TO IB
Monday, May 18, 2020FINAL DISPOSITION PROCESSED
Monday, May 4, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, February 4, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, November 19, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 19, 2019PUBLISHED FOR OPPOSITION
Friday, November 15, 2019NOTIFICATION PROCESSED BY IB
Wednesday, October 30, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, October 30, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, October 30, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, October 17, 2019ASSIGNED TO LIE
Thursday, October 10, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, September 20, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 20, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 20, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, April 6, 2019REFUSAL PROCESSED BY IB
Thursday, March 21, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, March 21, 2019REFUSAL PROCESSED BY MPU
Tuesday, March 12, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, March 11, 2019NON-FINAL ACTION WRITTEN
Friday, March 8, 2019APPLICATION FILING RECEIPT MAILED
Monday, March 4, 2019ASSIGNED TO EXAMINER
Monday, March 4, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 1, 2019LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, February 28, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

freeline disorders specification order others pharmaceutical system manufacturing inflammatory storage lysosomal